Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats

被引:12
作者
Bjorklund, Tomas [1 ]
Hall, Helene [1 ]
Breysse, Nathalie [1 ]
Soneson, Charlotte [1 ,2 ]
Carlsson, Thomas [1 ]
Mandel, Ronald J. [3 ]
Carta, Manolo [1 ,4 ]
Kirik, Deniz [1 ]
机构
[1] Lund Univ, Dept Expt Med Sci, BRAINS, S-22184 Lund, Sweden
[2] Lund Univ, Ctr Math Sci, S-22184 Lund, Sweden
[3] Univ Florida, Coll Med, Dept Neurosci, Powell Gene Therapy Ctr,McKnight Brain Inst, Gainesville, FL 32610 USA
[4] Lund Univ, Dept Expt Med Sci, Div Neurobiol, S-22184 Lund, Sweden
基金
瑞典研究理事会; 美国国家卫生研究院;
关键词
dopamine; enzyme replacement; GTP cyclohydrolase-1; Parkinson's disease; recombinant adeno-associated viral vector; tyrosine hydroxylase; HUMAN TYROSINE-HYDROXYLASE; MEDIATED GENE-TRANSFER; GTP-CYCLOHYDROLASE I; BEHAVIORAL RECOVERY; INDUCED DYSKINESIAS; MOLECULAR-GENETICS; DISEASE; MODEL; BRAIN; NOREPINEPHRINE;
D O I
10.1111/j.1471-4159.2009.06340.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Viral vector-mediated gene transfer is emerging as a novel therapeutic approach with clinical utility in treatment of Parkinson's disease. Recombinant adeno-associated viral (rAAV) vector in particular has been utilized for continuous l-3,4 dihydroxyphenylalanine (DOPA) delivery by expressing the tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1) genes which are necessary and sufficient for efficient synthesis of DOPA from dietary tyrosine. The present study was designed to determine the optimal stoichiometric relationship between TH and GCH1 genes for ectopic DOPA production and the cellular machinery involved in its synthesis, storage, and metabolism. For this purpose, we injected a fixed amount of rAAV5-TH vector and increasing amounts of rAAV5-GCH1 into the striatum of rats with complete unilateral dopamine lesion. After 7 weeks the animals were killed for either biochemical or histological analysis. We show that increasing the availability of 5,6,7,8-tetrahydro-l-biopterin (BH4) in the same cellular compartment as the TH enzyme resulted in better efficiency in DOPA synthesis, most likely by hindering inactivation of the enzyme and increasing its stability. Importantly, the BH4 synthesis from ectopic GCH1 expression was saturable, yielding optimal TH enzyme functionality between GCH1 : TH ratios of 1 : 3 and 1 : 7.
引用
收藏
页码:355 / 367
页数:13
相关论文
共 32 条
[21]   Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders [J].
Lundberg, Cecilia ;
Bjorklund, Tomas ;
Carlsson, Thomas ;
Jakobsson, Johan ;
Hantraye, Philippe ;
Deglon, Nicole ;
Kirik, Deniz .
CURRENT GENE THERAPY, 2008, 8 (06) :461-473
[22]  
Mandel RJ, 1998, J NEUROSCI, V18, P4271
[23]   INHIBITION OF GUINEA-PIG BRAIN TYROSINE-HYDROXYLASE BY CATECHOLS AND BIOPTERIN [J].
MANN, SP ;
GORDON, JI .
JOURNAL OF NEUROCHEMISTRY, 1979, 33 (01) :133-138
[24]   Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter:: Evidence from knock-out mouse lines [J].
Morón, JA ;
Brockington, A ;
Wise, RA ;
Rocha, BA ;
Hope, BT .
JOURNAL OF NEUROSCIENCE, 2002, 22 (02) :389-395
[25]   Combined 5-HTIA and 5-HTIB receptor agonists for the treatment of L-DOPA-induced dyskinesia [J].
Munoz, Ana ;
Li, Qin ;
Gardoni, Fabrizio ;
Marcello, Elena ;
Qin, Chuan ;
Carlsson, Thomas ;
Kirik, Deniz ;
Di Luca, Monica ;
Bjorklund, Anders ;
Bezard, Erwan ;
Carta, Manolo .
BRAIN, 2008, 131 :3380-3394
[26]  
NAGATSU T, 1964, J BIOL CHEM, V239, P2910
[27]   L-DOPA-INDUCED RELEASE OF CEREBRAL MONOAMINES [J].
NG, KY ;
CHASE, TN ;
COLBURN, RW ;
KOPIN, IJ .
SCIENCE, 1970, 170 (3953) :76-&
[28]   Optimizing levodopa phannacokinetics:: Intestinal infusion versus oral sustained-release tablets [J].
Nyholm, D ;
Askmark, H ;
Gomes-Trolin, C ;
Knutson, T ;
Lennernäs, H ;
Nyström, C ;
Aquilonius, SM .
CLINICAL NEUROPHARMACOLOGY, 2003, 26 (03) :156-163
[29]   Levodopa motor complications in Parkinson's disease [J].
Obeso, JA ;
Olanow, CW ;
Nutt, JG .
TRENDS IN NEUROSCIENCES, 2000, 23 (10) :S2-S7
[30]   ARE YOU USING NEURONAL DENSITIES, SYNAPTIC DENSITIES OR NEUROCHEMICAL DENSITIES AS YOUR DEFINITIVE DATA - THERE IS A BETTER WAY TO GO [J].
OORSCHOT, DE .
PROGRESS IN NEUROBIOLOGY, 1994, 44 (03) :233-247